UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

~~January 22~~February 19, 2026

Date of Report (date of earliest event reported)

Corcept Therapeutics Incorporated

(Exact name of registrant as specified in its charter)

Delaware

000-50679

77-0487658

(State or other jurisdiction
of incorporation)

(Commission

File Number)

(I.R.S. Employer
Identification No.)

101 Redwood Shores Parkway, Redwood City, CA 94065

(Address of Principal Executive Offices) (Zip Code)

(650) 327-3270

Registrant’s telephone number, including area code

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	CORT	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01.

Other Events.

On ~~January~~February 2219, 2026, Corcept Therapeutics Incorporated (the “Company”) issued a press release announcing that ~~ROSELLA,~~the United States Court of Appeals for the ~~Company~~Federal Circuit has found that Teva Pharmaceuticals’s ~~pivotal~~marketing ~~Phase~~of 3a ~~trial~~generic version of ~~relacorilant~~Korlym® ~~plus~~does ~~nab-paclitaxel~~not toinfringe ~~treat~~two ~~patients~~of ~~with~~the ~~platinum~~Company’s patents concerning methods of safely co-~~resistant~~administering ~~ovarian~~Korlym ~~cancer~~and drugs that inhibit the CYP3A4 enzyme, ~~met~~including ~~its~~drugs ~~overall~~that ~~survival~~are ~~primary~~commonly ~~endpoint~~prescribed to patients with Cushing’s syndrome. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01.

Financial Statements and Exhibits

(d) Exhibits

ExhibitsNo.		Description
99.1		Press Release of Corcept Therapeutics Incorporated, ~~January~~February 2219, 2026.
104.1		Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CORCEPT THERAPEUTICS INCORPORATED
Date: January 22, 2026	By:	/s/ Atabak Mokari
Date: February 19, 2026	By:	/s/ Atabak Mokari
	Name:	Atabak Mokari
	Title:	Chief Financial Officer

Filing Compare · CORCEPT THERAPEUTICS INC